- For the Russian Federation only, participants aged 15 to 23 months on the day of the first study visit (eligible for enrollment to MenACYW conjugate vaccine+PCV13 group or the PCV13 group) must not have received the third PCV13 vaccination corresponding to his or her age as per the country's National Immunization Program (NIP). The 2nd dose of PCV13 must have been administered at least 4 weeks before the 3rd dose of PCV13 is administered in the study.